
Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
Uva ursi contains arbutin, which converts to hydroquinone in alkaline urine, providing antimicrobial activity against urinary tract infection pathogens like E. coli. Clinical evidence shows mixed results for UTI treatment, with some studies indicating increased symptom burden despite potential antimicrobial effects.

Origin & History

Uva Ursi (Arctostaphylos uva-ursi) is a perennial evergreen shrub native to northern North America, Europe, and Asia, with leaves harvested as the primary medicinal part. The extract is typically obtained from dried leaves via aqueous or hydroalcoholic methods, yielding compounds dominated by phenolic glycosides, particularly arbutin (5-15% in dried leaves, standardized to 20-25% in extracts).
Research Narrative (Provisional)
Clinical evidence is limited to small RCTs in women with uncomplicated UTIs. The ATAFUTI trial (382 women, PMID:30685500) found no difference in symptom severity between uva-ursi and placebo, while Gágyor et al. (2021, PMID:34111592) reported reduced antibiotic use but increased symptom burden compared to fosfomycin. The REGATTA trial protocol (PMID:29970072) and ongoing NCT05055544 study aim to assess non-inferiority versus antibiotics.
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
Uva ursi is consumed as a medicinal herbal preparation (leaf tea, extract, or capsule), not as a food, so traditional macronutrient profiling (calories, protein, fat, carbohydrates) is not applicable at typical therapeutic doses. Key bioactive compounds include: • Arbutin (hydroquinone-β-D-glucopyranoside): 5–15% of dried leaf weight (primary active constituent); undergoes hydrolysis in alkaline urine to release hydroquinone, the antimicrobial metabolite. Standardized extracts typically deliver 100–210 mg arbutin per dose (equivalent to ~400–800 mg arbutin per day in divided doses). Bioavailability: arbutin is well absorbed orally and metabolized via gut microbiota and hepatic conjugation; urinary hydroquinone release is pH-dependent (optimal at urine pH >8). • Free hydroquinone: 0.1–0.5% of dried leaf; contributes directly to antimicrobial activity but also to hepatotoxicity concerns at high doses. • Tannins (gallotannins and ellagitannins): 15–20% of dried leaf weight, including corilagin, gallic acid, and ellagic acid; responsible for astringent properties and may contribute to anti-inflammatory and antidiarrheal effects. High tannin content may reduce bioavailability of co-ingested nutrients and medications. • Flavonoids: including hyperoside (quercetin-3-O-galactoside, ~0.5–1%), isoquercitrin, myricetin glycosides, and myricitrin; contribute antioxidant and mild anti-inflammatory activity. • Iridoid glycosides: including monotropein (trace to ~0.5%). • Triterpenes: ursolic acid (~0.4–0.8%) and oleanolic acid; associated with anti-inflammatory and hepatoprotective properties in preclinical models. • Phenolic acids: including gallic acid (~1–2%), p-coumaric acid, and syringic acid. • Allantoin: trace amounts; traditionally associated with tissue-soothing properties. • Minerals: Leaf material contains modest amounts of calcium, potassium, magnesium, and manganese typical of woody shrub foliage, but quantities delivered at therapeutic doses (1.5–4 g dried leaf/day) are nutritionally negligible. • Vitamins: No significant vitamin content at medicinal doses. • Fiber: Dried leaf contains insoluble plant fiber, but amounts consumed medicinally are too small to be dietarily relevant. Bioavailability notes: Arbutin absorption is rapid (Tmax ~1–2 hours); however, antimicrobial efficacy depends on urinary alkalinization (traditionally achieved by co-administration of sodium bicarbonate or alkaline diet). Tannin content may cause gastrointestinal irritation and reduce absorption of iron, alkaloids, and certain medications if co-administered. Prolonged use (>1–2 weeks) or high doses risk cumulative hydroquinone toxicity (hepatotoxicity, nephrotoxicity). The European Medicines Agency (EMA) recommends limiting use to 1 week and no more than 4 treatment episodes per year.
Reported Mechanism (Provisional)
Uva ursi's arbutin glycoside is hydrolyzed in the intestines and converted to hydroquinone in alkaline urine (pH >7). Hydroquinone exerts antimicrobial activity against gram-negative bacteria like E. coli by disrupting bacterial cell membranes and interfering with cellular metabolism. The effectiveness depends on urinary pH, requiring alkaline conditions for optimal hydroquinone formation and antibacterial activity.
Clinical Narrative (Provisional)
A 2021 systematic review (PMID:34111592) found mixed evidence for uva ursi in treating uncomplicated UTIs, with some studies showing potential reduction in antibiotic use but others indicating increased symptom burden. Most clinical trials have been small-scale with methodological limitations, making definitive efficacy conclusions difficult. Traditional use supports antimicrobial properties, but high-quality randomized controlled trials are limited. Current evidence suggests modest benefits that may not outweigh potential risks in all patients.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.







